Leadership

Bernd Brust brings more than 30 years of global leadership experience in life sciences and scientific instrumentation, with a focus on commercial operations, strategic growth, and innovation. Mr. Brust was appointed CEO and a Board Member of Maravai LifeSciences in June 2025.

Bernd brings more than 30 years of leadership experience in the life sciences industry. Previously, Bernd served as Executive Chairman and CEO of Antylia Scientific, a global provider of tools and solutions for diagnostic testing, sample preparation, biological monitoring, and environmental analysis. The company was a portfolio investment of private equity firm GTCR, which acquired Antylia in 2019 and sold it to Brookfield Asset Management for approximately $1.3 billion in 2025.

Before that, he was President and CEO of Qualicaps, a global provider of capsule manufacturing and processing equipment for the pharmaceutical industry, which was acquired by Mitsubishi Chemical Holdings in 2013.

Earlier in his career, Mr. Brust was Chief Commercial Operations Officer at Life Technologies Corporation, responsible for a $3.5 billion global business. He also held senior leadership positions at Invitrogen Corporation (a predecessor of Life Technologies) and GE Medical Systems, where he gained broad experience across operational, sales, and business development functions.

Raj Asarpota brings nearly 30 years of global executive leadership experience, including more than a decade as CFO of public and private life sciences and medical device companies. He was appointed Executive Vice President and Chief Financial Officer of Maravai LifeSciences in June 2025.

Raj joins Maravai with a strong track record of driving performance, advancing strategic initiatives, and scaling operations through organic growth and strategic acquisitions. Most recently, he served as EVP and CFO of Augmedics, a medical device company that develops augmented reality surgical navigation systems, with a focus on spine surgery, where he scaled commercial operations, raised capital, and led a strategic IP acquisition.

Previously, he was EVP and CFO of NuVasive, where he helped increase market capitalization by $1.2 billion and delivered significant margin expansion. He also served as CFO and COO of Cole-Parmer, where he led the company’s carve-out from Thermo Fisher Scientific. His earlier career includes key financial and operational leadership roles at Questcor Pharmaceuticals, Life Technologies, and GE Healthcare.

In his role at Maravai, Raj oversees the company’s global Finance, Accounting, Treasury, Investor Relations, Corporate Strategy, and Information Technology functions.

Mr. Asarpota holds an MBA from Marquette University and a Bachelor of Commerce from the University of Mumbai.

Pete Leddy has over 30 years of experience leading growth and change across a wide variety of businesses, and specifically in scaling global healthcare companies. Throughout 2022, Pete worked as a consultant to Maravai on a number of issues related to organizational design, compensation and retention before joining the Company as CAO. Previously, Pete served as Chief Human Resources Officer at Berkeley Lights, Chief People Officer at dosist, Executive Vice President, Global Human Resources and Corporate Integrity at Nuvasive and Chief Human Resources Officer at Life Technologies and Invitrogen. Earlier in his career he held a variety of executive and human resource positions at Dell, Promus Hotel Corp. and PepsiCo. He received his B.A. in Psychology from Creighton University and his M.S. and Ph.D. degrees in industrial/organizational psychology from the Illinois Institute of Technology.

Becky Buzzeo has more than 20 years of commercial leadership experience. Before joining Maravai, in October of 2022, she was the Vice President and General Manager, Advanced Therapies, at Thermo Fisher Scientific, where she oversaw CDMO services for plasmid DNA, cell therapy and mRNA. Prior to that, Mrs. Buzzeo led commercial operations at Brammer Bio and held commercial roles of increasing responsibility at Patheon Biologics and Life Technologies, before its acquisition by Thermo Fisher in 2014. Mrs. Buzzeo holds a B.S. in biology from Slippery Rock University of Pennsylvania.

Dr. Kate Broderick has more than 15 years of experience in the life science industry. A recognized vaccine expert, Dr. Broderick has a broad background in device and product development in the DNA therapeutic and drug delivery field. Prior to joining Maravai in 2022, Dr. Broderick held roles of increasing responsibility at Inovio Pharmaceuticals, most recently as Senior Vice President, R&D. Dr. Broderick has served as a principal investigator for a variety of grants and awards from government agencies and non-profits, including the National Institutes of Health. She received her PhD from the University of Glasgow in Scotland and completed her post-doctoral research at the University of California, San Diego.

Christine Dolan has served as the Chief Operating Officer of Maravai LifeSciences’ Biologics Safety Testing business segment since October 2017. Prior to joining Maravai, Ms. Dolan held several operational and business leadership roles including Senior Vice President of Product Development, VP of Global Operations and VPGM of Development and Analytical Services at Catalent Pharma Solutions. Prior to joining Catalent Pharma Solutions, she was Director of Nuclear Operations and Global Quality Control at GE Healthcare and Amersham Health. Dolan holds a B.S. in biology from Lenoir-Rhyne College.

Kurt Oreshack joined Maravai LifeSciences as General Counsel in November 2020. Prior to joining Maravai, Mr. Oreshack was a partner at Breakwater Law Group, practicing in the field of corporate and securities law. Prior to joining Breakwater Law Group, he was the General Counsel of Human Longevity, and previously practiced law individually and as General Counsel in Residence at Gunderson Dettmer Stough Villeneuve Franklin & Hachigian. Mr. Oreshack received a J.D. from the University of Notre Dame Law School and a B.A. from Loyola University Chicago. He is a member of the State Bar of California.